Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir | Zendy

Viktor von Wyl | Zendy; Sabine Yerly | Zendy; Jürg Böni | Zendy; Philippe Bürgisser | Zendy; Thomas Klimkait | Zendy; Manuel Battegay | Zendy; Enos Bernasconi | Zendy; Matthias Cavassini | Zendy; Hansjakob Furrer | Zendy; Bernard Hirschel | Zendy; Pietro Vernazza | Zendy; Martin Rickenbach | Zendy; Bruno Ledergerber | Zendy; Huldrych F. Günthard | Zendy

Open Access

Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir

Author(s) -

Viktor von Wyl,

Sabine Yerly,

Jürg Böni,

Philippe Bürgisser,

Thomas Klimkait,

Manuel Battegay,

Enos Bernasconi,

Matthias Cavassini,

Hansjakob Furrer,

Bernard Hirschel,

Pietro Vernazza,

Martin Rickenbach,

Bruno Ledergerber,

Huldrych F. Günthard

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/528863

Subject(s) - efavirenz , medicine , didanosine , confidence interval , resistance mutation , reverse transcriptase inhibitor , reverse transcriptase , virology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , polymerase chain reaction , genetics , gene

The human immunodeficiency virus type 1 reverse-transcriptase mutation K65R is a single-point mutation that has become more frequent after increased use of tenofovir disoproxil fumarate (TDF). We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research